Replimune (REPL) Debt to Equity (2023 - 2025)

Replimune's (REPL) quarterly Debt to Equity came in at $0.23 in Q4 2025, up 137.43% year-on-year from $0.1 in Q4 2024, and up 26.2% quarter-over-quarter from $0.18 in Q3 2025.

Replimune (REPL) Debt to Equity (2023 - 2025) Analysis & Trends

Replimune has disclosed Debt to Equity across 3 years of filings, most recently posting $0.23 for Q4 2025.

  • Debt to Equity for Q4 2025 came in at $0.23, up 137.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $0.23 (up 137.43% YoY), and the FY2025 annual result was $0.11, down 6.79% from the prior year.
  • Debt to Equity came in at $0.23 for Q4 2025 at Replimune, up from $0.18 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.23 in Q4 2025 to a low of $0.05 in Q1 2023.
  • The 3-year median for Debt to Equity is $0.12 (2024), against an average of $0.13.
  • Peak annual rise in Debt to Equity reached 137.43% in 2025, while the deepest fall reached 6.79% in 2025.
  • Replimune's Debt to Equity stood at $0.05 in 2023, then jumped by 84.68% to $0.1 in 2024, then soared by 137.43% to $0.23 in 2025.
  • The last three Debt to Equity figures came in at $0.23 (Q4 2025), $0.18 (Q3 2025), and $0.14 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 0.32
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -
9 Abivax 91.71 Bn 91.71 Bn - -
10 Replimune 780.01 Mn 510.88 Mn - 0.23

Historic Data

Download Data
DateValue
Dec 31, 2025 0.23
Sep 30, 2025 0.18
Jun 30, 2025 0.14
Mar 31, 2025 0.11
Dec 31, 2024 0.10
Sep 30, 2024 0.12
Jun 30, 2024 0.11
Mar 31, 2024 0.12
Mar 31, 2023 0.05